Grant: Operating Grant: Targeting High Fatality Cancers - Innovation Grant
McGill University
$100,000.00
Arresten as a biomarker and therapeutic for Pancreatic cancer
FY 2015-16
Summary
Pancreatic cancer is one of the most lethal of all cancers. Survival rates after 5 years are less than 5% and little or no progress has been made in treating this disease in over 30 years. One of the major genetic mutations leading to pancreatic cancer is the gene encoding the p53 tumour suppressor. The p53 tumour suppressor protein is the main factor that protects humans from cancer. More than half of pancreatic cancers have mutations in the p53 gene. Dr. Teodoro is studying a natural inhibitor of tumour growth that is regulated by p53 called Arresten. Research from the Teodoro lab suggests that the abundance of Arresten in the blood may determine the predisposition of individuals to develop pancreatic cancer. Dr. Teodoro's research group have recently developed a simple blood test to measure levels of Arresten and have found that Arresten levels are lower in the blood of lung cancer patients. In this proposal they will study how p53 regulates Arresten levels and if we can manipulate Arresten as a cancer diagnostic or therapy.
Department
Program
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
341760
Name
Teodoro Jose G
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Targeting High Fatality Cancers Innovation Grant
Projecttitle
Arresten as a biomarker and therapeutic for Pancreatic cancer
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Keyworddelim
Angiogenesis; Biomarker; Mouse Models; P53; Pancreatic Cancer; Pre-Clinical Models; Serum Markers; Xenografts
Abstract
Pancreatic cancer is one of the most lethal of all cancers. Survival rates after 5 years are less than 5% and little or no progress has been made in treating this disease in over 30 years. One of the major genetic mutations leading to pancreatic cancer is the gene encoding the p53 tumour suppressor. The p53 tumour suppressor protein is the main factor that protects humans from cancer. More than half of pancreatic cancers have mutations in the p53 gene. Dr. Teodoro is studying a natural inhibitor of tumour growth that is regulated by p53 called Arresten. Research from the Teodoro lab suggests that the abundance of Arresten in the blood may determine the predisposition of individuals to develop pancreatic cancer. Dr. Teodoro's research group have recently developed a simple blood test to measure levels of Arresten and have found that Arresten levels are lower in the blood of lung cancer patients. In this proposal they will study how p53 regulates Arresten levels and if we can manipulate Arresten as a cancer diagnostic or therapy.
Competitiondate
201601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Teodoro, Jose G
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $100,000~ $0~